Live Breaking News & Updates on Affinity asset advisors

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Update

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Update
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , Nasdaq , Promis-neurosciences-inc , Promis-neurosciences-company-profile , Affinity-asset-advisors , Exchange-commission , Get-free-report , Asset-advisors , Free-report , Collective-coordinates ,

Vincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Vincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states , Vincerx-pharma , Citadel-advisors , Sage-rhino-capital , Affinity-asset-advisors , Vanguard-group-inc , Cantor-fitzgerald , Vincerx-pharma-inc , Get-free-report , Rhino-capital , Asset-advisors , Springs-capital-management

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Update

ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 24,000 shares, a growth of 21.8% from the February 29th total of 19,700 shares. Based on an average trading volume of 46,700 shares, the days-to-cover ratio […]

Canada , Affinity-asset-advisors , Exchange-commission , Promis-neurosciences-inc , Nasdaq , Get-free-report , Asset-advisors , Free-report , Collective-coordinates ,

StockNews.com Initiates Coverage on Calithera Biosciences (NASDAQ:CALA)

StockNews.com Initiates Coverage on Calithera Biosciences (NASDAQ:CALA)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

California , United-states , South-san-francisco , Calithera-biosciences , Alyeska-investment-group , Goldman-sachs-group-inc , Vanguard-group-inc , Renaissance-technologies , Affinity-asset-advisors , Calithera-biosciences-inc , Get-free-report , Sachs-group

COMPASS Pathways (NASDAQ:CMPS) Sees Large Volume Increase

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) saw an uptick in trading volume on Thursday . 358,701 shares traded hands during mid-day trading, a decline of 46% from the previous session’s volume of 666,186 shares.The stock last traded at $8.90 and had previously closed at $9.50. Analyst Ratings Changes Several research firms recently issued […]

United-kingdom , United-states , George-jay-goldsmith , Ekaterina-malievskaia , Affinity-asset-advisors , Pathways-company-profile , Vivo-capital , Investment-management , Deutsche-bank-aktiengesellschaft , Nasdaq , Get-free-report , Bank-aktiengesellschaft

Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst Upgrade

Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst Upgrade
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states , Christopher-morabito , Jefferies-financial-group , Perceptive-advisors , Driehaus-capital-management , Securities-exchange-commission , Sphera-funds-management , Astria-therapeutics-inc , Affinity-asset-advisors , Nasdaq , Jump-financial , Perceptive-advisors-llc

Needham & Company LLC Reaffirms Buy Rating for Viridian Therapeutics (NASDAQ:VRDN)

Needham & Company LLC reaffirmed their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $30.00 price objective on the stock. Other analysts also recently issued reports about the stock. Oppenheimer lifted their price […]

Canada , Montreal , Quebec , Royal-bank , Affinity-asset-advisors , Vanguard-group-inc , Viridian-therapeutics-inc , Nasdaq , Fairmount-funds-management-llc , Securities-exchange-commission , Viridian-therapeutics-company-profile

Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 6.7%

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report)’s share price rose 6.7% during trading on Tuesday . The company traded as high as $10.51 and last traded at $10.40. Approximately 48,160 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 445,373 shares. The stock had previously closed at […]

Harris-rotman , Securities-exchange-commission , Centessa-pharmaceuticals-price-performance , Rathbones-group , Jefferies-financial-group , Affinity-asset-advisors , News-ratings-for-centessa-pharmaceuticals-daily , Centessa-pharmaceuticals , Institutional-trading-of-centessa-pharmaceuticals , Platinum-investment-management-ltd , Nasdaq , Acuta-capital-partners

Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from an underweight rating to a neutral rating in a research note published on Friday, MarketBeat Ratings reports. JPMorgan Chase & Co. currently has $14.00 target price on the stock. Several other brokerages also recently weighed in on TEVA. The Goldman […]

United-states , Los-angeles , California , Israel , America , Piper-sandler , Amir-weiss , Mark-sabag , News-ratings-for-teva-pharmaceutical-industries-daily , Teva-pharmaceutical-industries-price-performance , Barclays , Acadian-asset-management

Seven Eight Capital LP Purchases Shares of 41,556 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Seven Eight Capital LP purchased a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,556 shares of the biopharmaceutical company’s stock, valued at approximately $620,000. A number of other […]

Janet-dorling , Raymond-james , Piper-sandler , Sujal-shah , Cymabay-therapeutics-inc , Glenmede-trust-co , Nasdaq , Exchange-commission , Group-plc , Alps-advisors-inc , Affinity-asset-advisors , Seven-eight-capital